# US 2013/0296279 A1 · Substituted tetracyclines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0296279 A1
- Document ID: US20130296279A1
- Status: Published application
- Kind: A1
- Application number: 13/892,031
- Filed: 2013-05-10
- Published: 2013-11-07
- Earliest claimed: 2010-11-11
- Assignees: Concert Pharmaceutcals Inc.
- Applicants: Concert Pharmaceutcals Inc.
- Inventors: Adam Morgan
- Web page: https://patentgrep.com/patent/US20130296279A1

## CPC

- C07C 237/26: of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 207/09: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 221/18: Ring systems of four or more rings
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention in one embodiment is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention is also directed to a composition comprising the compound of formula I or a pharmaceutically acceptable salt, and methods of treating the indications listed herein.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
V is CH or N;
W is F;
each X is independently selected from H and D;
each Y is independently selected from CH3 and CD3;
Z is H; NH2; C1-C6 alkylene-R1 wherein the C1-C6 alkylene is optionally substituted with deuterium; or NHQR1;
Q is —C(O)— or a direct bond;
R1 is C0-C6 alkyl optionally substituted with deuterium and optionally substituted with R4; or NH(C1-C6 alkyl) wherein the C1-C6 alkyl is optionally substituted with deuterium;
R4 is NR2R3; or a 3- to 10-membered heterocyclyl containing at least one ring nitrogen wherein the 3- to 10-membered heterocyclyl is optionally substituted with deuterium at a carbon atom and is optionally substituted with C1-C6 alkyl that is optionally substituted with deuterium;
each of R2 and R3 is independently H; C1-C6 alkyl; (C3-C8 cycloalkyl); or (C0-C2)alkylene(C3-C8 cycloalkyl); wherein each C1-C6 alkyl, (C3-C8 cycloalkyl), and (C0-C2)alkylene(C3-C8 cycloalkyl) of R2 and R3 is independently optionally substituted with deuterium;
with the proviso that if W is other than CD3, OCD3 or N(CD3)2; each X is H; and each Y is CH3;
then Z comprises deuterium;
and with the proviso that if W is N(CH3)2 or N(CD3)2, then X5 is D and at least one of X1a, X1b, X2a, X2b, X3 and X4 is hydrogen.

### Claim 2 (depends on 1)

A compound of claim 1, wherein X1a and X1b are the same; X2a and X2b are the same; Y1 and Y2 are the same; and Z is H; NH2; or C1-C5 alkylene-R1 where the C1-C5 alkylene is optionally substituted with deuterium; or NHQR1.

### Claim 3 (depends on 1, 2)

A compound of claim 1 or 2, wherein X5 is deuterium.

### Claim 4 (depends on 1)

A compound of claim 1, wherein X1a and X1b are each hydrogen.

### Claim 5 (depends on 1)

A compound of claim 1, wherein X1a and X1b are each deuterium.

### Claim 6 (depends on 1)

A compound of claim 1, wherein V is CH.

### Claim 7 (depends on 6)

A compound of claim 6, wherein W is F; X1a and X1b are the same; X2a and X2b are the same; and Y1 and Y2 are the same.

### Claim 8 (depends on 7)

A compound of claim 7, wherein X1a, X1b, X2a and X2b are each hydrogen.

### Claim 9 (depends on 8)

A compound of claim 8, wherein Z is H, CH2NHCH2C(CH3)3, NHCOCH2C(CH3)3, NHCOCH2NHCH2CH3, NHCOCH2NHCH2CH2CH3, NHCOCH2NHCH2CH2CH2CH3, NHCOCH2NH-cyclopentyl, NHCOCH2NH-cyclobutyl, NHCOCH2NHCH2-cyclopropyl, NHCOCH2NHCH2-cyclobutyl, NHC(O)CH2N(CH3)2, NHC(O)CH2N(CH2CH3)(CH3), NHC(O)CH2(1-pyrrolidyl), NHCO—(S)-2-pyrrolidyl, NHCO—(S)-2-azetidinyl, NHCO—(S)-2-(N-methyl)-azetidyl, or —NHCO—(S)-2-(N-methyl)-pyrrolidyl, wherein Z is optionally substituted with deuterium.

### Claim 10 (depends on 1)

A compound of claim 1, wherein V is N.

### Claim 11 (depends on 10)

A compound of claim 10, wherein W is F; X1a and X1b are the same; X2a and X2b are the same; and Y1 and Y2 are the same.

### Claim 12 (depends on 11)

A compound of claim 11, wherein X1a, X1b, X2a and X2b are each hydrogen.

### Claim 13 (depends on 12)

A compound of claim 12, wherein Z is NH2, NHCH2CH3, NHCH2CH2CH3, NHCH2C(CH3)2CH2N(CH3)2, or NHCH2C(CH3)2CH2(1-pyrrolidyl), wherein Z is optionally substituted with deuterium.

### Claim 14 (depends on 1)

The compound of claim 1, wherein the compound of formula I is a compound of formula Ia
or pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

The compound of claim 1, wherein any atom not designated as deuterium is present at its natural isotopic abundance

### Claim 16 (depends on 1)

A pyrogen-free pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt of said compound; and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 16)

The composition of claim 16 additionally comprising a second therapeutic agent useful in the treatment or prevention of a disease or condition selected from cIAI, HAP, VAP, cSSSI, cUTI and CABP.

### Claim 18 (depends on 16)

A method of treating a patient suffering from, or susceptible to, a disease or condition selected from cIAI, HAP, VAP, cSSSI, cUTI and CABP, comprising the step of administering to the patient in need thereof an effective amount of a composition of claim 16.

### Claim 19 (depends on 1)

The compound of claim 1, wherein V is CH; each of X2a, X2b, X3 and X4 is hydrogen; Z is
and wherein the compound is selected from any of the compounds (Cmpd) set forth in the table below:
Cmpd
W
X1a
X1b
X5
Y1
Y2
254a
F
H
H
D
CH3
CH3
255a
F
H
H
D
CD3
CD3
256a
F
H
H
H
CD3
CD3
257a
F
D
D
D
CD3
CD3
258a
F
D
D
D
CH3
CH3
259a
F
D
D
H
CH3
CH3
260a
F
D
D
H
CD3
CD3
or a pharmaceutically acceptable salt thereof, wherein any atom not designated as deuterium is present at its natural isotopic abundance.

### Claim 20 (depends on 1)

The compound of claim 1, wherein V is CH; each of X2a, X2b, X3 and X4 is hydrogen; Z is
and wherein the compound is selected from any of the compounds (Cmpd) set forth in the table below:
Cmpd
W
X1a
X1b
X5
Y1
Y2
408a
F
H
H
H
CH3
CH3
409a
F
H
H
D
CH3
CH3
410a
F
H
H
D
CD3
CD3
411a
F
H
H
H
CD3
CD3
412a
F
D
D
D
CD3
CD3
413a
F
D
D
D
CH3
CH3
414a
F
D
D
H
CH3
CH3
415a
F
D
D
H
CD3
CD3
or a pharmaceutically acceptable salt thereof, wherein any atom not designated as deuterium is present at its natural isotopic abundance.
